What is the appropriate management for a 37‑week pregnant woman with hypertension (BP up to 157/98 mm Hg), proteinuria (~37 mg/L urine albumin), elevated alanine aminotransferase, and low serum magnesium?

Management of Hypertension with Proteinuria and Laboratory Abnormalities at 37 Weeks Gestation

This patient requires immediate hospitalization, initiation of antihypertensive therapy with extended-release nifedipine or labetalol, magnesium sulfate for seizure prophylaxis, and delivery planning at 37 weeks given the constellation of preeclampsia with severe features. 1

Immediate Clinical Assessment and Diagnosis

This presentation is consistent with preeclampsia with severe features based on:

• Severe-range blood pressure: Morning BP of 157/98 mmHg meets criteria for hypertension (≥140/90 mmHg), with systolic BP >160 mmHg associated with adverse maternal outcomes including stroke and pulmonary edema 1
• Proteinuria: Urine albumin 36.9 mg/L indicates proteinuria, though the degree of proteinuria does not correlate with outcomes and should not guide management intensity 2
• Elevated transaminases: ALT 84.5 U/L suggests hepatocellular injury, a marker of end-organ damage 3
• Low magnesium: 0.68-0.71 mmol/L (below normal 0.74) may reflect renal losses or hemodilution 3

Urgent Management Priorities

Hospitalization and Monitoring

All patients with suspected preeclampsia require hospitalization in obstetric centers with adequate maternal and neonatal intensive care resources. 1

• Close BP monitoring with treatment targets to prevent hemorrhagic stroke 1
• Laboratory surveillance including liver enzymes, platelet count, and renal function to detect HELLP syndrome or disease progression 3
• Continuous fetal monitoring for well-being 3

Blood Pressure Management

Initiate antihypertensive therapy immediately given BP readings approaching severe range:

• First-line agents: Extended-release nifedipine (preferred for once-daily dosing improving adherence) OR labetalol 4, 1
• Treatment threshold: BP ≥140/90 mmHg in the setting of gestational hypertension with organ damage 1
• Target BP: <140/90 mmHg to reduce maternal morbidity while avoiding utero-placental hypoperfusion 3, 5
• Avoid methyldopa for urgent BP reduction 1

If BP reaches ≥160/110 mmHg lasting >15 minutes, this constitutes a hypertensive emergency requiring immediate IV labetalol or oral nifedipine. 1

Magnesium Sulfate Administration

Magnesium sulfate is mandatory for seizure prophylaxis in preeclampsia with severe features:

• Prevents eclamptic seizures and reduces maternal mortality 1, 3
• Critical caveat: Do NOT administer concomitantly with calcium channel blockers (nifedipine) due to risk of severe hypotension from synergistic effects 1
• If using nifedipine for BP control, carefully time magnesium sulfate administration with close hemodynamic monitoring 1

Magnesium Supplementation

Correct the low serum magnesium (0.68-0.71 mmol/L):

• Oral magnesium supplementation can be initiated for the deficiency 3
• This is separate from magnesium sulfate for seizure prophylaxis, which achieves much higher therapeutic levels 1

Delivery Planning

Plan for delivery at 37 weeks gestation (current gestational age):

• Preeclampsia with severe features at term (≥37 weeks) is an indication for delivery 1, 3
• Induction of labor should be attained after 37 weeks per guidelines 1
• Continuing pregnancy beyond 37 weeks with preeclampsia increases maternal risk without fetal benefit 3

Critical Pitfalls to Avoid

Aspirin Initiation at This Stage

Do NOT start aspirin at 37 weeks - this patient has no current aspirin therapy:

• Low-dose aspirin (81-162 mg daily) is effective for preeclampsia prevention when started at 12-16 weeks gestation 3, 6
• Starting aspirin at 37 weeks provides no benefit and delivery is imminent 3
• Aspirin is a preventive measure, not a treatment for established preeclampsia 6

Proteinuria Monitoring

Do not repeatedly measure proteinuria to guide management:

• The amount of proteinuria does not correlate with maternal or neonatal outcomes 2
• Management is based on BP severity and end-organ damage (elevated ALT), not protein levels 2
• Repeated proteinuria assessment may lead to unnecessary preterm deliveries 2

Blood Pressure Treatment Targets

Avoid aggressive BP lowering to <120/70 mmHg:

• Excessive BP reduction may compromise utero-placental perfusion 5
• Target BP <140/90 mmHg balances maternal stroke prevention with fetal safety 3, 5

Postpartum Considerations

Hypertensive disorders account for up to 44% of pregnancy-related deaths in the first 6 days postpartum:

• Close BP monitoring required for at least 6 days postpartum 3
• Preeclampsia can worsen or present de novo after delivery 4, 3
• Continue antihypertensive therapy postpartum; labetalol, nifedipine, enalapril, and metoprolol are safe for breastfeeding 1
• BP should normalize by 12 weeks postpartum; persistent elevation requires chronic hypertension workup 4

Long-term Cardiovascular Risk

This patient has significantly increased lifetime cardiovascular disease risk:

• Annual BP monitoring is mandatory after hypertensive disorders of pregnancy 4, 3
• Increased risk of chronic hypertension, stroke, and cardiovascular disease independent of traditional risk factors 5, 7
• Obstetric history should be incorporated into future cardiovascular risk assessment 7